Tags

Type your tag names separated by a space and hit enter

Studies of selective and reversible monoamine oxidase inhibitors.
J Clin Psychiatry. 1984 Jul; 45(7 Pt 2):62-6.JC

Abstract

Several selective and reversible monoamine oxidase inhibitors (MAOIs) have recently become available. Preliminary studies suggest that these compounds have antidepressant effects and may offer significant safety and side effect advantages over classical MAOIs. Pilot studies with 1-deprenyl, a selective MAO-B inhibitor, indicate that it may be most effective for patients with nonendogenous depression and for those (endogenous or nonendogenous) who present with certain reverse vegetative signs. The drug appears ineffective in depressed patients with associated panic attacks and phobic symptoms. An alternative approach in the development of safer, effective MAOIs is the use of rapidly reversible MAO-A inhibitors, such as moclobemide, that carry less risk of a hypertensive reaction and yet appear to be effective antidepressants. As selective MAO-A and MAO-B inhibition may be effective in different depressive subtypes and may have different side effects, these drugs are valuable pharmacologic probes for studying the biochemical bases of depressive disorders.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6429130

Citation

Mann, J J., et al. "Studies of Selective and Reversible Monoamine Oxidase Inhibitors." The Journal of Clinical Psychiatry, vol. 45, no. 7 Pt 2, 1984, pp. 62-6.
Mann JJ, Aarons SF, Frances AJ, et al. Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiatry. 1984;45(7 Pt 2):62-6.
Mann, J. J., Aarons, S. F., Frances, A. J., & Brown, R. D. (1984). Studies of selective and reversible monoamine oxidase inhibitors. The Journal of Clinical Psychiatry, 45(7 Pt 2), 62-6.
Mann JJ, et al. Studies of Selective and Reversible Monoamine Oxidase Inhibitors. J Clin Psychiatry. 1984;45(7 Pt 2):62-6. PubMed PMID: 6429130.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Studies of selective and reversible monoamine oxidase inhibitors. AU - Mann,J J, AU - Aarons,S F, AU - Frances,A J, AU - Brown,R D, PY - 1984/7/1/pubmed PY - 1984/7/1/medline PY - 1984/7/1/entrez SP - 62 EP - 6 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 45 IS - 7 Pt 2 N2 - Several selective and reversible monoamine oxidase inhibitors (MAOIs) have recently become available. Preliminary studies suggest that these compounds have antidepressant effects and may offer significant safety and side effect advantages over classical MAOIs. Pilot studies with 1-deprenyl, a selective MAO-B inhibitor, indicate that it may be most effective for patients with nonendogenous depression and for those (endogenous or nonendogenous) who present with certain reverse vegetative signs. The drug appears ineffective in depressed patients with associated panic attacks and phobic symptoms. An alternative approach in the development of safer, effective MAOIs is the use of rapidly reversible MAO-A inhibitors, such as moclobemide, that carry less risk of a hypertensive reaction and yet appear to be effective antidepressants. As selective MAO-A and MAO-B inhibition may be effective in different depressive subtypes and may have different side effects, these drugs are valuable pharmacologic probes for studying the biochemical bases of depressive disorders. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/6429130/Studies_of_selective_and_reversible_monoamine_oxidase_inhibitors_ DB - PRIME DP - Unbound Medicine ER -